Skip Navigation


JAC Advance Access originally published online on April 21, 2007
Journal of Antimicrobial Chemotherapy 2007 60(1):159-161; doi:10.1093/jac/dkm116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
60/1/159    most recent
dkm116v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sreenivas, K.
Right arrow Articles by Chakrabarti, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sreenivas, K.
Right arrow Articles by Chakrabarti, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vitro and in vivo antibacterial evaluation of DRF 8417, a new oxazolidinone

K. Sreenivas*, P. V. S. Amarnath, A. Mallik, H. Sarnaik, N. Selva Kumar, M. Takhi, S. Trehan, M. Sitaram Kumar, J. Iqbal, R. Rajagopalan and R. Chakrabarti

Anti-infective Group, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad 500 049, India

Received 10 December 2006; returned 8 February 2007; revised 22 March 2007; accepted 27 March 2007

* Corresponding author. Tel: +91-40-2304-5439, ext. 260; Fax: +91-40-2304-5438; E-mail: sreenivaskandepu{at}drreddys.com

Objectives and methods: DRF 8417, a novel oxazolidinone, has been evaluated against Gram-positive and fastidious Gram-negative bacteria. In vitro activity of DRF 8417 was determined by broth microdilution method and in vivo efficacy studies were carried out in different murine systemic infection models.

Results: DRF 8417 exhibited potent activity against Gram-positive pathogens with MIC50 and MIC90 values ranging from 0.06 to 1 mg/L. MICs against Haemophilus influenzae and Moraxella catarrhalis were one to two dilutions lower than those of linezolid. The in vivo efficacy, by oral route, in different susceptible and resistant Gram-positive systemic bacterial infection models ranged from 2.0 to 2.9 mg/kg.

Conclusions: These studies displayed the excellent in vitro and in vivo activity of DRF 8417 against Gram-positive pathogens and lower MICs when compared with linezolid against H. influenzae and M. catarrhalis.

Keywords: clinical isolates , systemic infection models , linezolid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. J. Hilliard, J. Fernandez, J. Melton, M. J. Macielag, R. Goldschmidt, K. Bush, and D. Abbanat
In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2028 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Kalia, R. Miglani, K. P. Purnapatre, T. Mathur, S. Singhal, S. Khan, S. R. Voleti, D. J. Upadhyay, K. S. Saini, A. Rattan, et al.
Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1427 - 1433.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.